 |
|
|
| |
Estimating the HCV treatment reach in high-risk groups in order to meet 2030 WHO elimination targets
|
| |
| |
AASLD 2022 Nov 4-8
Stevens W1, Marx SE2, Jiao S2, Collins MA2, Kaur J2, Jeffries D.1
1. Medicus Economics, LLC, Boston, Massachusetts, USA
2. AbbVie Inc., North Chicago, Illinois, USA
|
| |
|
|
|
|
|
